Introduction. Female genital chronic graft-versus-host disease (cGvHD) is a complication of allogeneic hematopoietic cell transplantation (alloHCT) for blood malignancies. Unattended inflammation and fibrosis in the vulva and vagina may lead to total vaginal stenosis. The course and treatment of genital cGvHD was observed in this population-based prospective study. Material and methods. Women (n = 41) receiving alloHCT in 2005-10 were examined before and at 3, 6, 9, 12, 18, 24, 30 and 36 months post-transplant. Vulvovaginal signs were documented, National Institutes of Health clinical scores were calculated, and women completed questionnaires on symptoms, the Female Sexual Distress Scale and the Beck Depression Inventory. Local immunosuppressive treatment was given weekly. Results. Genital cGvHD was diagnosed in 27 women (incidence 56% at 12 months; 66% at 36 months); extragenital cGvHD was found in 21/27. The most common signs at diagnosis were red and white spots, reticular white lines, fissures, synechiae and telangiectasia; symptoms included dryness, itching, dyspareunia, pain or no symptoms. Thirteen women were treated on a schedule of tacrolimus and clobetazol ointments. Although some signs progressed during treatment, only two women developed total stenosis. At 36 months, 12 women still had genital cGvHD. Conclusions. Genital cGvHD develops mainly in the first year after alloHCT. Early intervention may halt its progress to severe fibrosis, but despite correct diagnosis and treatment, symptoms and signs may become chronic. Women who develop genital cGvHD following alloHCT require life-long gynecological supervison and care.
Introduction
Female genital chronic graft-versus-host disease (cGvHD) is a common but previously overlooked complication of allogeneic hematopoietic stem cell transplantation (alloHCT). The curative potential of alloHCT is due to the combination of preparative chemo/radiotherapy and the graft-versus-leukemia effect, an immunological antitumor action exerted mainly by the donor's T lymphocytes. Unfortunately, the benefits of allografting are hampered by procedure-related toxicity and mortality. After alloHCT, most patients develop graft-versus-host disease (GvHD), an attack of donor immunocompetent cells on the patient's healthy tissues. Acute GvHD is characterized by early onset, and liver, skin and gut symptoms, whereas cGvHD is typically associated with progressive inflammation and fibrosis of mucous membranes in the mouth, conjunctivae and genitals. Extensive fibrosis may lead to scleroderma, bronchiolitis or total vaginal stenosis (1) .
After the first publication on female genital cGvHD (2), several studies have accounted for its signs, prevalence and symptoms (3) (4) (5) (6) (7) (8) , including sexual dysfunction (6) (7) (8) (9) (10) . In a cross-sectional study of 42 women examined at median 80 (range 13-148) months after alloHCT (8) , 52% had clinical signs of genital cGvHD according to National Institutes of Health (NIH) criteria (11) . Partial or complete vaginal stenosis was found in 41% (n = 9) of the women.
In the present prospective study, a defined cohort of women was followed up with frequent gynecological examinations before and up to 3 years after transplant. Our aims were to describe the course, signs and symptoms of genital cGvHD; to increase knowledge about its diagnosis; and to prevent or alleviate disabling genital cGvHD through early intervention with local treatment.
Material and Methods

Patient description and study design
Fifty-two women scheduled for alloHCT from September 2005 to February 2010 in the Swedish Western Health Region were eligible for inclusion. The inclusion criterion was having completed alloHCT, although initial recruitment began during the pre-alloHCT gynecologic examination. Forty-one women were included, median age 46 years (17-66 years); four declined to participate, five died or relapsed early, and two participated in a competing study. The women came for gynecologic examination before and 3, 6, 9, 12, 18, 24, 30 and 36 months after alloHCT. Gynecologic examination included structured documentation of vulvovaginal signs by one or both of the assigned specialists in Obstetrics and Gynecology (ESK and A-KB). The vulva was documented photographically at most visits. Occasionally patients were seen between study visits. Regular post-transplant follow ups and treatments were conducted at the Hematology Section, Sahlgrenska University Hospital, Gothenburg. The incidence and severity of extragenital cGvHD were gathered from medical records. At each study visit, the woman completed a comprehensive questionnaire on her general gynecological and medical history, gynecological symptoms, local and systemic medication (see Supplementary material, Table S1 ) (12) ; the Female Sexual Distress Scale (FSDS), and the Beck Depression Inventory (BDI). Symptoms of genital dysfunction were selfreported as occurring never, seldom, sometimes, often or always. A score of ≥ 15 in the FSDS was used as the cutoff for sex-related personal distress (13) . On the BDI, scores for depression ≥ 14 are ranked mild, ≥ 20 are ranked moderate and ≥ 29 are ranked severe (14, 15) .
Diagnosis and scoring of genital cGvHD
The NIH 2005 consensus crieria defining diagnostic and distinctive signs (11) were used to diagnose and score genital and extragenital cGvHD (Table 1) . Diagnoses were given for at least one diagnostic sign or one distinctive sign + histologic biopsy showing genital cGvHD or one distinctive sign + any cGvHD found elsewhere. Diagnostic signs include vulvar lichen-planus-like features such as reticular white lines, erythematous patches, redness, erosive areas, teleangiectatic areas, vulvar synechiae, labial fusion and resorption (Figure 1) , vaginal synechiae or scarring, partial stenosis and complete vaginal stenosis (16) . Distinctive signs include erosions, fissures and ulcers. We also considered as a diagnostic sign a specific form of vaginal scarring, presenting as tender filamentous fibrous strand or sore fibrotic string (6, 8) . This can be felt at gynecologic examination as a more or less circular string in the vaginal wall, sore to the touch, but not visible to the eye. We also registered as distinctive signs red and white spots on the mucosa giving a mottled appearance
Key Message
Genital chronic graft-versus-host disease develops primarily during the first year after transplant, with mild signs at onset. Treatment intervention may halt its progression to severe genital chronic graft-versus-host disease. Women diagnosed with genital chronic graftversus-host disease should have life-long follow up and treatment.
(8) and signs not specific to cGvHD such as edema and thin and dry mucosa.
Treatment
Hormone replacement therapy was prescribed to all women in premature menopause. Local estrogen was prescribed to all women before any other local treatment. Local immunosuppressive ointments, clobetasol (0.05%) and tacrolimus (0.1-0.03%) were prescribed as first-line therapy for genital cGvHD and a dilator was recommended for vaginal cGvHD (Table 2) . We followed a structured treatment schedule, modified if necessary according to symptoms and signs. The rationale for the treatment schedule was a combination of the current Swedish recommendations for treatment of genital lichen sclerosis, the published reports on tacrolimus use for atopic dermatitis and cutaneous cGvHD (17, 18) , and in-house hematology experience. Systemic oral corticosteroids were not included in the treatment schedule and if taken were prescribed by the hematologist.
Statistical analyses
Mann-Whitney U-test and chi-squared test were used, and p < 0.05 was considered statistically significant.
Ethical approval
The study was approved by the Regional Ethical Review Board of Gothenburg (Dnr 194-06). All women gave their written informed consent before their first study-associated gynecological examination.
Results
Study population
Of the 41 women included, 29 were followed over 36 months after transplant. Remaining patients were lost at a median of seven months (4-17 months) due to disease relapse (n = 7), or other causes (n = 5). At transplant, 16 patients were already in natural menopause and four were in premature menopause. The remaining 21 women developed premature menopause 3-18 months' after transplant. There was no association between genital cGvHD and hematologic diagnosis, donor (sibling/unrelated), or pre-transplant conditioning (reduced/myeloablative).
Incidence and prevalence
Genital cGvHD was diagnosed in 27 (66%) of the 41 women, 23 (85%) of whom were diagnosed in the first year after alloHCT ( Figure 2 ). Median time to first confirmed sign was 6 months (1-30 months). Twenty of the 27 women with genital cGvHD were followed for 36 months. At 36 months, the prevalence of genital and extragenital cGvHD was 12/29 (41%) and 8/29 (28%), respectively. Ten of the 12 women with genital cGvHD at 36 months were diagnosed ≤ 12 months, one at 24 months, and one at 30 months. The cumulative incidence of genital cGvHD 
Signs and symptoms at first diagnosis of genital cGvHD
Signs defined as diagnostic, distinctive and not specific to genital cGvHD at the first diagnosis of all 27 women are presented in Table 3 . Thin and dry genital mucosa were the most common signs before and after transplant (see Supplementary material, Table S2 ). The first sign of genital cGvHD was in the vulva in 18 women, in the vagina in four, and in both the vulva and vagina in five women. Throughout the study, 15/27 women had genital cGvHD in both vulva and vagina. Fibrotic signs at onset were vulvar and vaginal synechia (n = 5 for each). Partial or total stenosis was only seen later. Fibrosis was seen in a total of 23 (85%) women during the study. Partial stenosis (n = 5) appeared at a median of 9 months (0.5-14 months) after the debut of genital cGvHD. Two of these five women later developed total stenosis.
Self-reported symptoms at first diagnosis of genital cGvHD are shown in Figure 3 . Itching, dryness, pain and burning were the most common vulvar symptoms, but Gentle painless use includes lubricant, slow insertion, waiting for muscular contractions to relax before continuing insertion and leaving the dilator in the vagina for 3-5 min. eight women were without any symptoms. Self-reported symptoms from all women at each time-point are described in the Supplementary material (Table S3) . At first diagnosis, six of the 13 sexually active women experienced dyspareunia. The study protocol did not include continuous cervical smear sampling. As the risk of developing atypia after alloHCT has been noted, we performed a retrospective survey of the medical records. Pathologic cervical smear was noted in 15 (37%) of the 41 women during the study period. Of these 15, 11 were also diagnosed with genital cGvHD.
BDI and FSDS scores
Women with or without genital cGvHD differed significantly in their BDI scores. At six and 24 months after alloHCT, the presence of genital cGvHD was associated with higher BDI (p = 0.011 and p = 0.024, respectively) (see Supplementary material, Table S2 ). Of the total study cohort, 29% of the responders reported maximum FSDS (≥ 15) at 24 months after alloHCT vs. 18% before and at 36 months after alloHCT. FSDS scores did not show a significant difference between the groups with and without genital cGvHD at any time. Mild to severe depression (BDI ≥ 14) was present in 27% of the women before alloHCT and in 10-17% at all times after alloHCT. Five women had co-existing depression (BDI ≥ 14) and sexual distress (FSDS ≥ 15) during 1-3 years.
Treatment of genital cGvHD
Of the 27 women diagnosed, 13 started the treatment schedule for genital cGvHD (Table 2 ) at a median of 9
(1-31) months after alloHCT (Supporting Information, Table S2 ). Fourteen women did not receive loval immunosuppressive treatment because of pathological Pap smear, infection, relapse, fluctuation or disappearance of signs, or no symptoms. Local immunosuppressive treatment was started in the vulva, the vagina, or both according to signs and symptoms. Preemptive treatment of non-affected areas did not protect from progression in most women. Temporary burning sensations were reported by nine women at treatment start. A dilator was used by seven women with fibrotic vaginal cGvHD. Treatment intensitity was often increased because of relapsed cGvHD after a period of less frequent medication (n = 7). The median treatment duration was 15 (3-35) months. We noted outside the protocol that progression correlated over time with lowering systemic oral corticosteroids in 4/6 women. Four women recovered with local treatment in a median of 8 (3-33) months. At 36 months, five of the 12 women with genital cGvHD were on the treatment schedule, four had maintenance treatmen, one had completed treatment, and two had not been treated. At 36 months, three women were without symptoms, four had symptoms only rarely, four had symptoms varying over time, and one had symptoms more often than at treatment start. Dyspareunia in sexually active women decreased during the study from 47% (8/17) at 6 months to 29% (4/14) at 36 months. Clinical scoring was used to classify the impact of cGvHD on the affected organ by combining signs and symptoms into one of four categories (Table 1) . NIH 2005 clinical scores 1 and 2 dominated and were relatively unchanged over the study period (Figure 4 ). Clinical score 0 (no symptoms independently of signs) was the largest category 9 months after alloHCT, whereas clinical scores of 1-3 (mild to severe symptoms with mild to advanced signs) increased from 12 to 18 months, suggesting that signs of genital cGvHD may precede symptoms.
Discussion
To our knowledge this is the first prospective cohort study of genital cGvHD in allografted women. A consecutive group of women (n = 41) were continually examined over 36 months, and their genital symptoms and signs were recorded and treated. We found that genital cGvHD debuted within the first year after transplant (median 6 months) in 85% of the women, with a cumulative incidence (CI) of 56% at 12 months and 66% at 36 months.
Other investigators report slightly later onset to diagnosis (9-13 months) and lower incidences (35-49%) (5-7).
The CI was higher in this study than in previous retrospective studies (3) (4) (5) 7) . This may be due to late referral, patient selection, poor coverage, short follow up or differences in diagnostic criteria. The CI of extragenital cGvHD peaked at 6 months after alloHCT (68%), in line with previous findings that 73-90% of women with newly diagnosed genital cGvHD already had extragenital cGvHD (3, 5, 6) . One aim of the present study was to increase knowledge of early signs and symptoms of genital cGvHD. Typically, the first signs of genital cGvHD (reticular white lines, synechiae, fissures, telangiectasia, and red and white spots) appeared in the vulva before the vagina (6) , and progression to the vagina was almost inevitable despite local preemptive immunosuppressive treatment. We noticed the first signs of cGvHD usually in the vulva (n = 18), but also in the vagina (n = 4) or both (n = 5). At diagnosis, we found that dryness, itching, burning, pain with or without touch, increased discharge and dyspareunia were the most common symptoms (4) (5) (6) (7) .
Notably, almost 30% of the women with signs of genital cGvHD in this study were asymptomatic at diagnosis and would have gone untreated had we followed recommendations to conduct gynecologic examinations only annually or in case of symptoms (19, 20) . Therefore, we recommend that regular gynecologic examinations be routine procedure during the first 3-18 months post transplant in allografted women. Although cGvHD may be located only in the genital region (6, 20, 21) , any clinical sign of cGvHD elsewere, such as keratoconjunctivitis sica, should also be suspected to herald an outbreak of genital cGvHD.
Our results on the FSDS questionnaire showed less sexual distress (14-29%) than other studies (9, 10, 22) . In addition to dyspareunia, problems with sexual dysfunction, libido, sexual activity and satisfaction affect 66-80% of female survivors of alloHCT (10, 22) . The BDI scores for depression in this study were also lower than in other studies (10, 23) . According to Humphreys et al., assessing and addressing depression at the pretransplant stage may reduce sexual dysfunction in long-term survivors (9) . We used the BDI and FSDS questionnaires at each visit to discuss each woman's situation regarding depression and sexual function. Therefore, our approach included psychosexual intervention that might have influenced our results. The low figures for depression might also contribute to the lower figures for sexual personal distress (9) , as depression is one of the main causes of lowered sexual desire (24) .
In this study, we hypothesized that local early intervention might halt the inflammatory cGvHD process in women with clinical scores of 0-1 and decrease their risk of developing severe fibrosis. Although clobetasol and tacrolimus applied locally to the vulva hindered neither the development of vaginal cGvHD nor, in some cases, its progression to vaginal fibrosis (20, 21) , clinical scores of 1-2 remained almost constant throughout the study. Moreover, in our previous cross-sectional study, 8/42 women were diagnosed with vaginal stenosis before 36 months (8) compared with 2/41 in the current study. This indicates that active monitoring to diagnose the disease and begin immediate treatment may prevent severe fibrosis. Local estrogen treatment should always be the first drug of choice for women presenting with clinical score of 0-1, and when other genital cGvHD treatments are introduced, estrogen should be continued (5,7). Stratton et al. describe faster recovery from genital cGvHD in women with estrogen therapy than in those without (6) . Although some consider local estrogen a risk factor for genital cGvHD and recommend starting it after local immunosuppressive treatment (3, 21) , we found that distinctive and diagnostic signs could disappear at least temporarily during local estrogen treatment. A scoring system grades the severity of the disease and is useful not only for following individual women over time, but also for between-group and between-study assessments. In the current study, conducted in 2005-13, we used a slightly modified NIH 2005 clinical scoring system for cGvHD (11) . In 2014, the NIH published an updated scoring system not including symptoms (25) . We acknowledge that some different signs for diagnosing and scoring genital cGvHD have been suggested by other authors, making comparisons difficult (3) (4) (5) (6) (7) 25) .
Genital cGvHD, similar to cGvHD in other locations, may become a chronic condition with signs and symptoms that fluctuate. Of the 12 women with genital cGvHD at 36 months, 10 were diagnosed before 12 months post alloHCT. However, most reported sporadic or no symptoms. During the study, we became aware that tapering of systemic corticoid steroids may trigger genital cGvHD. We also noted that outside the protocol, immunosuppressive treatment may activate the human papillomavirus and increase the risk of cervical epithelial cell atypia (21, 26) . As steroid treatment is the mainstay of managing both acute and chronic GvHD, close cooperation with the hematologist is essential. Another possible improvement in care would be to intensify daily local immunosuppressive treatment, as described by Stratton et al. (6) .
In practice, we propose a protocol for all women receiving alloHCT including gynecological examination three to four times in the first year and every 6-12 months thereafter, depending on other cGvHD, local symptoms and the feasibility of surveillance by vaginal self-examination. A woman diagnosed with genital cGvHD should have life-long follow up to detect and treat flare-ups and secondary malignancies. Estrogen, local immunosuppressive treatment, dilator, and systemic corticoid steroids for aggressive disease are the mainstays of treatment for genital cGvHD.
Conclusions
Genital cGvHD develops primarily during the first year after transplant and its incidence is high. A clinical score of 0-1 on the NIH criteria for genital cGvHD is most common at onset. Although treatment intervention may halt progression to severe genital cGvHD, signs and symptoms fluctuate with or without local treatment and the disease is likely to last for more than 36 months. Hematologists and gynecologists must cooperate to balance local and systemic corticosteroid treatments and improve the care of women with cGvHD. Table S1 . Comprehensive questionnaire adapted from the national Swedish Vulva Group (Swedish Society of Obstetrics and Gynecology). Table S2 . Signs, treatment, Female Sexual Distress Scale (FSDS), Beck Depression Inventory (BDI) and dyspareunia in 41 women with and without genital chronic graftversus-host disease (cGvHD) seen before, 6, 12, 24 and 36 months after allogeneic hematopoietic stem cell transplantation (alloHCT). Table S3 . Self-reported symptoms in 41 women with and without genital chronic graft-versus-host disease (cGVHD) seen before, 6, 12, 24 and 36 months after allogeneic hematopoietic cell transplantation (alloHCT).
